急性副鼻腔炎の成人例に対するCDTR-PIの高用量投与治療（200mg/回×3回/日）の有用性の検討

DOI Web Site 参考文献16件

書誌事項

タイトル別名
  • Clinical Efficacy of High-dose Administration (200 mg 3 times daily) of CDTR-PI in Treating Acute Sinusitis and Acute Aggravation of Chronic Sinusitis in Adults
  • 薬物 急性副鼻腔炎の成人例に対するCDTR-PIの高用量投与治療(200mg/回×3回/日)の有用性の検討
  • ヤクブツ キュウセイ フクビコウエン ノ セイジンレイ ニ タイスル CDTR-PI ノ コウヨウリョウ トウヨ チリョウ(200mg/カイ × 3カイ/ヒ)ノ ユウヨウセイ ノ ケントウ

この論文をさがす

抄録

Drug-resistant S. pneumoniae and H. influenzae, which have been major causes for otolaryngological infections are now being more frequently detected in recent years. In contrast, Cefditoren Pivoxil (CDTR-PI) still preserves high antibacterial activity against both PRSP and BLNAR which are common drug-resistant bacteria, and high-dose medication with this drug is recommended at the time of acute sinusitis or acute aggravation of chronic sinusitis. However, there have been few reports on the clinical efficacy of high-dose administration of CDTR-PI in the treatment of adult sinusitis. Here we examined the clinical efficacy of the treatment of CDTR-PI 200 mg 3 times daily in the treatment of these diseases.<br> CDTR-PI 200 mg was prescribed 3 times daily for 7 to 14 days (8.2±2.2 days) in 61 patients who came for consultation during the period from June, 2009 to December, 2010. The clinical efficacy rate of the doctor’s judgment was 89.8% (53/61). Based on the scoring judgment, marked improvement was demonstrated in 20 patients, and moderate improvement was found in 30 cases, which meant that 50 of 61 (82.0%) patients exhibited remarkable improvement. S. pneumoniae was detected in 7 patients, eradicated in 3 patients, and decreased in 1 patient. H. influenzae was detected in 8 patients, eradicated in 4 patients, and decreased in 2 patients. Adverse events were observed in 8 patients with diarrhea but it was not serious.<br> In conclusion, the treatment with CDTR-PI 200 mg 3 times daily was found effective for acute sinusitis or acute aggravation of chronic sinusitis in adults.<br>

収録刊行物

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ